Protillion Biosciences specializes in the design and development of protein-based drugs.
Protillion Biosciences has raised $18.0M in total funding. The most recent round was Series A. The last funding was announced in December 2022.
Protillion Biosciences's investors include ARCH Venture Partners, Illumina Ventures.
Protillion Biosciences is headquartered in Burlingame, United States.
Protillion Biosciences specializes in the design and development of protein-based drugs.
Protillion Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Protillion Biosciences — Funding & Investors." VCBacked, December 19, 2022, https://www.vcbacked.co/company/protillion-biosciences. Accessed September 16, 2026.
VCBacked. (2022). Protillion Biosciences — Funding & Investors. Retrieved September 16, 2026, from https://www.vcbacked.co/company/protillion-biosciences
{{cite web |title=Protillion Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/protillion-biosciences |website=VCBacked |access-date=September 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated